Article Text

Download PDFPDF
Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with atrial fibrillation (AF), is clopidogrel plus aspirin non-inferior to oral anticoagulation for preventing vascular events?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Haematology ★★★★★★★


Embedded ImageDesign:

randomised controlled trial (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events [ACTIVE W]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (outcome assessors and monitoring committee).*

Embedded ImageFollow up period:

median 1.28 years.

Embedded ImageSetting:

30 clinical centres worldwide.

Embedded ImagePatients:

6706 patients (mean age 70 y, 66% men) with AF and ⩾1 of the following criteria: age ⩾75 years; receiving treatment for systemic hypertension; previous stroke, transient ischaemic attack, or non-central nervous system (non-CNS) systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; peripheral arterial disease; or age 55–74 years with diabetes mellitus requiring drug therapy …

View Full Text


  • * See glossary.

  • Sources of funding: Sanofi Aventis and Bristol Myers Squibb.

    Sources of funding: Sanofi-Aventis and Bristol-Myers Squibb

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd